arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development
September 27, 2010
- ARGX-109 and Two Further Human Antibody Development Candidates Generated From Unique SIMPLE Antibody™ platform
Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), today announced that it has received a €1.5 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space.